Skip to content
Screener

NeoGenomics NEO Reportable Segment — NET REVENUE

Similar metrics at other companies

Zevra Therapeutics, Inc. logo
ZVRAReportable Segment — Revenue, net
$39.66M+53.3%
Rimini Street, Inc. logo
RMNIReportable Segment — Revenue
$105.47M+1.2%
Twist Bioscience Corporation logo
TWSTReportable Segment — Revenue
$110.72M+19.3%
Lifecore Biomedical, Inc. logo
LFCRReportable Segment — Revenue
$34.17M—
Akamai Technologies logo
AKAMReportable Segment — Revenue
$1.1B+5.4%
Accel Entertainment logo
ACELReportable Segment — Total net revenues
$340.8M+7.1%

Other financials

Income statement

See full
Revenue$201.7M+11.2%
Gross profit$91.9M+18.9%
Operating income-$9.8M+79.5%
Net income$2.2M+105%
EPS (diluted)$0.02+106%

Balance sheet

See full
Cash & equivalents$145.5M-5.9%
Total debt$448.4M+534%
Total equity$785.7M-8.0%
Total assets$1.4B-3.0%

Cash flow

See full
Operating cash flow$20.0M-1.8%
CapEx$8.2M+30.0%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$2B+182%
Enterprise value$2.3B+268%
P/S2.6×+1.6×

Profitability

See full
Gross margin43.9%0.0pp
Operating margin-8.9%-2.8pp
Net margin-6.8%-2.4pp
FCF margin-4.9%—

Returns & leverage

See full
Return on equity-6.3%-2.0pp
Debt / equity0.6×+0.5×
Current ratio3.6×-0.3×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001077183-26-000059
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Net revenue$201,656$181,330$388,328$349,365
Less:
Amortization7,6348,12415,26716,486
Depreciation8,5779,14117,35718,507
Stock-based compensation8,21612,21517,85222,969
Other cost of revenue(1)101,83195,525199,715181,342
Other general and administrative(1)48,56952,83697,614103,585
Other research and development(1)9,9347,85918,39316,961

Item 1. Financial Statements (unaudited)

FAQ

What is NeoGenomics's reportable segment — NET REVENUE?
NeoGenomics (NEO) reported reportable segment — NET REVENUE of $201.66M in Q2 2026.
How has NeoGenomics's reportable segment — NET REVENUE changed year-over-year?
NeoGenomics's reportable segment — NET REVENUE increased by 11.2% year-over-year, from $181.33M to $201.66M.
What is the long-term trend for NeoGenomics's reportable segment — NET REVENUE?
Over 3 years (2022 to 2025), NeoGenomics's reportable segment — NET REVENUE has grown at a 12.6% compound annual growth rate (CAGR), from $509.73M to $727.33M.
What does reportable segment — NET REVENUE mean?
Represents the total gross revenue generated by the business segment after deducting returns, allowances, and discounts. This metric serves as the primary indicator of the segment's market demand and top-line growth performance.

Ask your AI about NeoGenomics's reportable segment — net revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude